Niels Junker

988 total citations
30 papers, 745 citations indexed

About

Niels Junker is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Niels Junker has authored 30 papers receiving a total of 745 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 17 papers in Immunology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Niels Junker's work include CAR-T cell therapy research (17 papers), Immunotherapy and Immune Responses (16 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Niels Junker is often cited by papers focused on CAR-T cell therapy research (17 papers), Immunotherapy and Immune Responses (16 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Niels Junker collaborates with scholars based in Denmark, Italy and United States. Niels Junker's co-authors include Inge Marie Svane, Per thor Straten, Mads Hald Andersen, Eva Ellebæk, Marco Donia, Sine Reker Hadrup, Rikke Andersen, Ton N. Schumacher, Özcan Met and Rikke Lyngaa and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Niels Junker

28 papers receiving 731 citations

Peers

Countries citing papers authored by Niels Junker

Since Specialization

Citations

This map shows the geographic impact of Niels Junker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Niels Junker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Niels Junker more than expected).

Fields of papers citing papers by Niels Junker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Niels Junker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Niels Junker. The network helps show where Niels Junker may publish in the future.

Co-authorship network of co-authors of Niels Junker

This figure shows the co-authorship network connecting the top 25 collaborators of Niels Junker. A scholar is included among the top collaborators of Niels Junker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Niels Junker. Niels Junker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	β-adrenergic signaling blockade attenuates metastasis through activation of cytotoxic CD4 T cells 2025 ·Nature Communications ·(unknown), Astrid Z. Johansen, (unknown), Kevin James Baker, (unknown), (unknown), Marie‐Louise Thorseth, Majken Siersbæk, (unknown), (unknown), (unknown), (unknown), Lars H. Engelholm, Inge Marie Svane, Mads Hald Andersen, Niels Junker, Lars Grøntved, Per thor Straten, Daniel H. Madsen	0
2	Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma 2023 ·Clinical Cancer Research ·Patrick Schöffski, Rastislav Bahleda, Andrew J. Wagner, Melissa Burgess, Niels Junker, Michael Chisamore, Patrick Peterson, Anna M. Szpurka, (unknown), William D. Tap	9
3	Blockade of beta-adrenergic receptors reduces cancer growth and enhances the response to anti-CTLA4 therapy by modulating the tumor microenvironment 2022 ·Oncogene ·(unknown), (unknown), (unknown), Astrid Z. Johansen, Marie‐Louise Thorseth, Marco Carretta, Lars H. Engelholm, Lars Grøntved, Niels Junker, Daniel H. Madsen	85
4	154P Results of an open-label, phase Ia/Ib study of olaratumab plus pembrolizumab in patients with unresectable, locally advanced or metastatic soft tissue sarcoma 2021 ·Annals of Oncology ·Patrick Schöffski, Rastilav Bahleda, Andrew J. Wagner, Melissa Burgess, Niels Junker, Michael Chisamore, Patrick Peterson, Marco Ceccarelli, (unknown)	1
5	In vitro 4-1BB stimulation promotes expansion of CD8+ tumor-infiltrating lymphocytes from various sarcoma subtypes 2020 ·Cancer Immunology Immunotherapy ·Morten Nielsen, Anders Krarup‐Hansen, (unknown), Michael Mørk Petersen, Anand C. Loya, Marie Christine Wulff Westergaard, Inge Marie Svane, Niels Junker	17
6	Management Recommendations for Merkel Cell Carcinoma—A Danish Perspective 2020 ·Cancers ·(unknown), Torben Steiniche, Morten Ladekarl, Marie Louise Bønnelykke‐Behrndtz, Lisbet Rosenkrantz Hölmich, Seppo W. Langer, (unknown), (unknown), (unknown), Mathilde Skaarup Larsen, Niels Junker, Annette H. Chakera	14
7	Pembrolizumab as first line treatment of Merkel cell carcinoma patients – a case series of patients with various co-morbidities 2020 ·Acta Oncologica ·(unknown), (unknown), Helle Westergren Hendel, Anders Krarup‐Hansen, Niels Junker	6
8	Severely Disseminated Kaposi Sarcoma after ABO-Incompatible Kidney Transplantation Treated Successfully with Paclitaxel and Gemcitabine Combined with Hemodialysis 2019 ·SHILAP Revista de lepidopterología ·(unknown), Anders Krarup‐Hansen, Martin Egfjord, Søren Schwartz Sørensen, Niels Junker	0
9	Expansion of tumor specific tumor-infiltrating lymphocytes (TIL) from sarcoma and the potential benefit of anti-CD137 stimulation: A prerequisite for adoptive cell transfer (ACT) immunotherapy 2017 ·Annals of Oncology ·Morten Nielsen, Anders Krarup‐Hansen, (unknown), Michael Mørk Petersen, Anand C. Loya, Marie Christine Wulff Westergaard, Inge Marie Svane, Niels Junker	1
10	Preclinical development of tumor-infiltrating lymphocyte (TIL) based adoptive cell transfer (ACT) immunotherapy for patients with sarcoma 2016 ·Annals of Oncology ·Morten Nielsen, Anders Krarup‐Hansen, (unknown), Michael Mørk Petersen, Anand C. Loya, Niels Junker, Inge Marie Svane	1
11	PD-L1 peptide co-stimulation increases immunogenicity of a dendritic cell-based cancer vaccine 2016 ·OncoImmunology ·Shamaila Munir Ahmad, Evelina Martinenaite, Morten Hansen, Niels Junker, Troels Holz Borch, Özcan Met, Marco Donia, Inge Marie Svane, Mads Hald Andersen	30
12	PD-L1 specific tumor infiltrating lymphocytes occur frequently in melanoma and HNSCC patients. 2014 ·Journal of Clinical Oncology ·Niels Junker, Marco Donia, Rikke Sick Andersen, Mads Hald Andersen, Inge Marie Svane	2
13	Dissection of T-cell Antigen Specificity in Human Melanoma 2012 ·Cancer Research ·Rikke Andersen, Charlotte Albæk Thrue, Niels Junker, Rikke Lyngaa, Marco Donia, Eva Ellebæk, Inge Marie Svane, Ton N. Schumacher, Per thor Straten, Sine Reker Hadrup	119
14	Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients 2012 ·Journal of Translational Medicine ·Eva Ellebæk, Trine Zeeberg Iversen, Niels Junker, Marco Donia, Lotte Engell-Noerregaard, Özcan Met, Lisbet Rosenkrantz Hölmich, Rikke Andersen, Sine Reker Hadrup, Mads Hald Andersen, Per thor Straten, Inge Marie Svane	134
15	Bimodal ex vivo expansion of T cells from patients with head and neck squamous cell carcinoma: a prerequisite for adoptive cell transfer 2011 ·Cytotherapy ·Niels Junker, Mads Hald Andersen, Lynn Wenandy, (unknown), Katalin Kiss, Christian Hjort Sørensen, Marianne Hamilton Therkildsen, Christian von Buchwald, Elo Andersen, Per thor Straten, Inge Marie Svane	29
16	Tumor associated antigen specific T-cell populations identified in ex vivo expanded TIL cultures 2011 ·Cellular Immunology ·Niels Junker, Pia Kvistborg, Tania Køllgaard, Per thor Straten, Mads Hald Andersen, Inge Marie Svane	21
17	Characterization and Comparison of ‘Standard’ and ‘Young’ Tumour‐Infiltrating Lymphocytes for Adoptive Cell Therapy at a Danish Translational Research Institution 2011 ·Scandinavian Journal of Immunology ·Marco Donia, Niels Junker, Eva Ellebæk, Mads Hald Andersen, Per thor Straten, Inge Marie Svane	85
18	The Immune System Strikes Back: Cellular Immune Responses against Indoleamine 2,3-dioxygenase 2009 ·PLoS ONE ·Rikke Bæk Sørensen, (unknown), Niels Junker, (unknown), Sine Reker Hadrup, Ton N. Schumacher, Inge Marie Svane, Jürgen C. Becker, Per thor Straten, Mads Hald Andersen	57
19	The immunodominant HLA-A2-restricted MART-1 epitope is not presented on the surface of many melanoma cell lines 2008 ·Cancer Immunology Immunotherapy ·Rikke Bæk Sørensen, Niels Junker, Alexei F. Kirkin, Heike Voigt, Inge Marie Svane, Jürgen C. Becker, Per thor Straten, Mads Hald Andersen	10
20	Superantigen Presentation by Human Retinal Pigment Epithelial Cells to T Cells is Dependent on CD2–CD58 and CD18–CD54 Molecule Interactions 2001 ·Experimental Eye Research ·(unknown), Niels Junker, Charlotte G. Kæstel, Ye Liang, Anne Katrine Wiencke, Morten la Cour, G M Lui, Niels Ødum, Mogens Holst Nissen, Carsten Röpke	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact